June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
LiGHT: Laser in Glaucoma and Ocular Hypertension Trial – Methodology and Baseline characteristics of a multicentre randomised controlled trial.
Author Affiliations & Notes
  • Gus Gazzard
    Glaucoma Research, Institute of Ophthalmology, London, United Kingdom
  • Evgenia Konstantakopoulou
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
    Institute of Ophthalmology, University College London, London, United Kingdom
  • David Garway-Heath
    Institute of Ophthalmology, University College London, London, United Kingdom
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
  • Keith Barton
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
  • Richard Wormald
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
    Institute of Ophthalmology, University College London, London, United Kingdom
  • Stephen Morris
    Department of Applied Health Research, Institute of Epidemiology & Health Care, University College London, London, United Kingdom
  • Rachael Hunter
    Priment Clinical Trials Unit, Royal Free Medical School, University College London, London, United Kingdom
  • Gary Rubin
    Institute of Ophthalmology, University College London, London, United Kingdom
  • Marta Buszewicz
    7. Research Department of Primary Care and Population Health, University College London, London, United Kingdom
  • Gareth Ambler
    Department of Statistical Science, Faculty of Mathematics & Physical Sciences, University College London, London, United Kingdom
  • Catey V Bunce
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
    Department of Primary Care and Public Health Sciences, King's College London, London, United Kingdom
  • Yuzhen Jiang
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
    Institute of Ophthalmology, University College London, London, United Kingdom
  • Victoria Vickerstaff
    Priment Clinical Trials Unit, Royal Free Medical School, University College London, London, United Kingdom
    Marie Curie Palliative Care Research Department, Division of Psychiatry, University College London, London, United Kingdom
  • nathwani neil
    NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
  • Footnotes
    Commercial Relationships   Gus Gazzard, Allergan (C), Moorfields Eye Charity (F), NIHR HTA (F); Evgenia Konstantakopoulou, Moorfields Eye Charity (F), NIHR HTA (F); David Garway-Heath, Aerie (C), Alcon (C), Allergan (C), Bausch&Lomb (C), Moorfields Eye Charity (F), NIHR HTA (F), Pfizer (F), Quark (C), Santen (C), Santhera (C); Keith Barton, Alcon (C), Allergan (F), Amakem (C), AMO (F), Aquesys Ophthalmic implants (I), Carl Zeiss MEditec (C), Glaucos (C), Ivantis (C), Kowa (C), London Claremont clinic (I), Merck (C), Moorfields Eye Charity (F), New World Medical (F), NIHR HTA (F), Ophthalmic Implants PTE Ltd (P), Refocus (F), Refocus (C), Santen (C), Thea (C), Transcend MEdical (C), Vision Futures Ltd (I), Vision Medical Events (I); Richard Wormald, Moorfields Eye Charity (F), NIHR HTA (F); Stephen Morris, NIHR HTA (F); Rachael Hunter, NIHR HTA (F); Gary Rubin, Moorfields Eye Charity (F), NIHR HTA (F); Marta Buszewicz, Moorfields Eye Charity (F), NIHR HTA (F); Gareth Ambler, Moorfields Eye Charity (F), NIHR HTA (F); Catey Bunce, NIHR HTA (F); Yuzhen Jiang, British Council for the Prevention of Blindness (F), Moorfields Eye Charity (F); Victoria Vickerstaff, None; nathwani neil, Moorfields Eye Charity (F), NIHR HTA (F)
  • Footnotes
    Support  National Institute Health Research - Health & Technology Assessment programme (12/LO/0940)
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 5574. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Gus Gazzard, Evgenia Konstantakopoulou, David Garway-Heath, Keith Barton, Richard Wormald, Stephen Morris, Rachael Hunter, Gary Rubin, Marta Buszewicz, Gareth Ambler, Catey V Bunce, Yuzhen Jiang, Victoria Vickerstaff, nathwani neil; LiGHT: Laser in Glaucoma and Ocular Hypertension Trial – Methodology and Baseline characteristics of a multicentre randomised controlled trial.. Invest. Ophthalmol. Vis. Sci. 2017;58(8):5574.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The Laser in Glaucoma and Ocular-Hypertension (LiGHT) Trial compares initial treatment with selective laser trabeculoplasty (SLT) versus topical medication for Primary Open Angle Glaucoma (POAG) and Ocular Hypertension (OHT).

Methods : LiGHT is a pragmatic, observer masked, multi-centre randomised controlled trial. 718 newly diagnosed patients with POAG or OHT were recruited at 6 collaborating centres in the United Kingdom between 2012-2014. Randomisation to SLT followed by conventional medical therapy as required or medical therapy without laser therapy was by done by an online web-based randomisation service, achieving full allocation concealment. Participants will be monitored for 3 years, according to routine clinical practice by masked observers. The target intraocular pressure (IOP) was based on disease severity and lifetime risk of loss of vision at recruitment and subsequently adjusted on the basis of IOP control and the stability of optic disc and visual field. The same decision support software determined treatment escalation and follow-up intervals to minimise bias. The primary outcome measure is Health Related Quality of Life (EQ-5D-5L). Secondary outcomes are treatment pathway cost and cost-effectiveness, Glaucoma Utility Index, Glaucoma Symptom Scale, Glaucoma Quality of Life, objective measures of pathway effectiveness, visual function and safety profiles and concordance. The sample size was determined for 90% power to detect a difference in mean EQ-5D-5L scores between treatment arms of 0.05 using a two-sample t-test at the 5% significance level, assuming a common standard deviation of 0.19 and allowing for 15% loss to follow-up at 36 months. A single main analysis will be performed at the end of the trial on an intention-to-treat basis.

Results : A total of 554 patients (77.2%) were classified as POAG and 163 patients (22.7%) as OHT. Median subject age was 63 years. The median IOP for OHT eyes was 26mmHg and 23mmHg for POAG eyes. The median for MD of baseline visual fields (VF) was -0.81dB for OHT eyes and -2.82dB for POAG eyes. POAG patients had similar median scores to OHT on the EQ-5D-5L (0.94) and GSS (85), higher scores on GQL (POAG 17, OHT 16) and lower GUI scores (POAG 0.90, OHT 0.93).

Conclusions : The LiGHT Trial will provide valuable data on HRQL, clinical- and cost-effectiveness of SLT and topical IOP lowering medication.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×